Skip to Main Content

An experimental pill from Sage Therapeutics that aimed to treat depression more rapidly than existing drugs failed its first large study in patients in major depression, a significant setback for the firm.

The drug, called SAGE-217, did not show a statistically significant, anti-depressive benefit compared with a placebo.

advertisement

Patients on the 30-milligram dose of the drug saw their scores on a measure known as the Hamilton Depression Rating Scale drop 12.6 points over 15 days, compared to a decrease of 11.2 points for those on placebo.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe

STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect

To submit a correction request, please visit our Contact Us page.